The Viral Hemorrhagic Fever Immunotherapeutic Consortium, or VIC, was established in 2014 to develop life-saving antibody therapeutics against some of the world’s deadliest viruses. The VIC represents a field-wide collaboration in which leading laboratories around the world have united to understand what fetaures lead to antibody-mediated protection againt these viruses and how we can more rapidly discover ideal treatments. This collaborative effort allows each laboratory to contribute their strengths in analytical techniques towards the identification, characterization, and validation of antibodies against the filoviridae and arenaviridae families. From isolating novel antibodies and testing them in vivo, to the structural analysis of the molecular mechanisms of neutralization, VIC scientists contribute unique insights towards the overall characterization of a broad pool of antibodies. The consortium is funded through a National Institute of Health National Institute of Allergy and Infectious Diseases Centers for Excellence in Translational Research program grant.